LAURUSLABSData path: financials for LAURUSLABS are currently sourced via the US ADR cross-listing (NYSE/NASDAQ). The fair value and score on this page reflect the latest cached compute against that data path. A direct NSE data path is in active development; values will refresh once it lands. How our data sourcing works →
Laurus Labs Limited
LAURUSLABS · Pharma · NSE
₹1,397
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for LAURUSLABS yet. Reason: Data Limited.
Updated 43m ago
YieldIQ Score
—
Piotroski F-Score
5/9
Economic Moat
None
Confidence
29%
ROE
8.0%
Debt/Equity
0.62
WACC
10.5%
Market Cap
₹75,402 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.5%
Return on capital employed
EV / EBITDA
46.4×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
3.3×
EBIT covers interest
Current Ratio
1.22×
Short-term liquidity
Asset Turnover
0.65×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-76.6%
3-year revenue growth
Revenue CAGR (5Y)
-56.3%
5-year revenue growth
Ratio Trends
LAURUSLABS · last 9 annual periods
ROE
8.0%
ROCE
15.5%
Operating Margin
—
Debt / Equity
0.62×
PE
0.2×
EV / EBITDA
1.4×
Historical Financials
LAURUSLABS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹4814 Cr | ₹4889 Cr | ₹6014 Cr | ₹5002 Cr | ₹5508 Cr | +3.4% |
| EBITDA | — | ₹1411 Cr | ₹1556 Cr | ₹793 Cr | ₹1121 Cr | -5.6% |
| EBIT | ₹1369 Cr | ₹1186 Cr | ₹1274 Cr | ₹419 Cr | — | -25.6% |
| PAT | ₹984 Cr | ₹828 Cr | ₹790 Cr | ₹161 Cr | ₹358 Cr | -22.3% |
| EPS (diluted) | ₹18.28 | ₹15.35 | ₹14.64 | ₹2.97 | — | -36.5% |
| CFO | ₹733 Cr | ₹911 Cr | ₹994 Cr | ₹666 Cr | ₹602 Cr | -4.8% |
| CapEx | — | ₹-877 Cr | ₹-990 Cr | ₹-678 Cr | ₹-641 Cr | — |
| FCF | — | ₹34.3 Cr | ₹3.7 Cr | ₹-12.6 Cr | ₹-39.4 Cr | — |
| Total Assets | — | ₹6968 Cr | ₹7660 Cr | ₹8387 Cr | ₹9336 Cr | +7.6% |
| Total Debt | — | ₹1777 Cr | ₹2015 Cr | ₹2577 Cr | ₹2764 Cr | +11.7% |
| Shareholders' Equity | — | ₹3351 Cr | ₹4038 Cr | ₹4111 Cr | ₹4473 Cr | +7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LAURUSLABS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 GLENMARK GLENMARK | — | — | Pending | 11.8% | — |
 ALKEM ALKEM | — | — | Pending | 16.7% | 27.5× |
 ABBOTINDIA ABBOTINDIA | — | — | Pending | 32.5% | 35.5× |
 AUROPHARMA AUROPHARMA | — | — | Pending | 9.2% | 21.4× |
 MANKIND Mankind Pharma Limited | -55.7% | 40 | Above Fair Value | 11.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹6.80/sh
Last payout
2025-10-31
₹0.80
Peak payout
₹1.20
Trailing yield
0.06%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of LAURUSLABS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LAURUSLABS →
Compare
Head-to-head with peers
Compare LAURUSLABS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LAURUSLABSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.